KnippeRx Revenue and Competitors

Charlestown, IN USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • KnippeRx's estimated annual revenue is currently $18.7M per year.(i)
  • KnippeRx's estimated revenue per employee is $201,000

Employee Data

  • KnippeRx has 93 Employees.(i)
  • KnippeRx grew their employee count by 22% last year.

KnippeRx's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.6M230%N/AN/A
#2
$23.5M117-28%N/AN/A
#3
$575.7M28642%N/AN/A
#4
$1.8M18-10%$1.5MN/A
#5
$5.8M29-6%N/AN/A
#6
$10.7M5315%N/AN/A
#7
$271.4M13504%N/AN/A
#8
$9.2M4610%N/AN/A
#9
$27760M443974%N/AN/A
#10
$1.2M6-54%N/AN/A
Add Company

What Is KnippeRx?

KnippeRx is a highly nimble, independent specialty pharmacy that was designed to serve the needs of the rare, orphan, and ultra-orphan drug categories and purpose-built to overcome the complex barriers to access, providing the shortest possible path from initiation of script to delivery of essential therapy. Our clear concentration enables us to provide exceptional services to manufacturers, patients, providers, and payers—never before offered in the specialty care environment. As a patient-centric focused pharmacy, KnippeRx provides personalized patient assistance that includes PAP and starter dispensing of specialty therapies, high-touch biologics, and other products requiring temperature control. KnippeRx is an affiliate of J. Knipper and Company, the largest supplier of end-to-end pharmaceutical samples in the United States. With the operational and logistical expertise of Knipper embedded in our DNA, KnippeRx provides seamless integrated solutions that address a myriad of patient access and specialty drug distribution challenges.

keywords:N/A

N/A

Total Funding

93

Number of Employees

$18.7M

Revenue (est)

22%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A973%N/A
#2
$29.9M10314%N/A
#3
$15M121N/AN/A
#4
$42.8M1444%N/A
#5
$48.2M167-22%$185.2M